Entrada reports Q3 2021 net loss $14.4M and closes $208.7M IPO

Entrada Therapeutics, Inc.

Net loss for Q3 2021 was $14.4M vs $7.0M in Q3 2020; R&D expense $10.5M, G&A $3.9M.
Closed upsized IPO in November, raising $208.7M gross ($190.9M net) at $20.00 per share.
IPO included full exercise of underwriters' option for 1.36M additional shares; total shares issued 10.44M.
Cash position as of Sep 30, 2021 was $122.2M, excluding IPO proceeds; post-IPO cash significantly strengthened.
Lead candidate ENTR-601-44 for DMD advancing toward initial clinical data; DM1 program entering development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.